First Reported Case of Unexpected Response to an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the I744M Uncommon EGFR Mutation

Clin Lung Cancer. 2015 Nov;16(6):e259-61. doi: 10.1016/j.cllc.2015.06.002. Epub 2015 Jun 24.

Authors

Emmanuelle Kempf¹, Ludovic Lacroix², Jean-Charles Soria³

Affiliations

¹ Gustave Roussy Cancer Campus, Drug Development Department and University Paris-Sud, Villejuif, France. Electronic address: emma@kempf.pro.
² Gustave Roussy Cancer Campus, Department of Medical Biology and Pathology, Translational Research Laboratory and Biobank (UMS3655 CNRS /US23 INSERM), INSERM Unit U981, Villejuif, France.
³ Gustave Roussy Cancer Campus, Drug Development Department and University Paris-Sud, Villejuif, France.

PMID: 26206728
DOI: 10.1016/j.cllc.2015.06.002

No abstract available

Keywords: Gefitinib; I744M mutation; Non–small-cell lung cancer; Oncogene addiction; Rare EGFR mutation.

Publication types

Case Reports

MeSH terms

Aged
Biomarkers, Pharmacological / metabolism*
Carcinoma, Non-Small-Cell Lung / diagnosis*
Carcinoma, Non-Small-Cell Lung / drug therapy
Carcinoma, Non-Small-Cell Lung / genetics
DNA Mutational Analysis
Diarrhea / etiology
ErbB Receptors / genetics
ErbB Receptors / metabolism*
Gefitinib
Humans
Lung Neoplasms / diagnosis*
Lung Neoplasms / drug therapy
Lung Neoplasms / genetics
Male
Mutation / genetics
Predictive Value of Tests
Protein Kinase Inhibitors / administration & dosage*
Protein Kinase Inhibitors / adverse effects
Quinazolines / administration & dosage*
Quinazolines / adverse effects
Respiratory Sounds / drug effects*
Respiratory Sounds / genetics
Treatment Outcome

Substances

Biomarkers, Pharmacological
Protein Kinase Inhibitors
Quinazolines
EGFR protein, human
ErbB Receptors
Gefitinib